
Investments
53Portfolio Exits
36Funds
1Partners & Customers
10Service Providers
2About GSK
GSK (GlaxoSmithKline) (NYSE: GSK) develops and markets pharmaceuticals, vaccines, over-the-counter medicines, and health care products. The company was founded in 1830 and is based in Middlesex, U.K.

Want to inform investors similar to GSK about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing GSK
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned GSK in 8 CB Insights research briefs, most recently on Aug 8, 2023.




Dec 17, 2020
5 Ways Digital Twins Could Improve Healthcare
Nov 11, 2020
Genomics Business Model Spotlight: HelixLatest GSK News
Sep 18, 2023
The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia. Myelofibrosis is an uncommon form of blood cancer that can cause an enlarged spleen; constitutional symptoms such as night sweats, fever and weight loss; and scarring in the bone marrow. The bone marrow scarring also leads to severe anemia, which can cause fatigue and weakness. Blood transplants and bone marrow transplants are among the few options available for treating this condition. Compounds such as ruxolitinib and danazol can be used to treat myelofibrosis but are unable to tackle anemia. GSK’s Ojjaara is a blocker of the proteins Janus kinase (JAK) 1 and 2 as well as activin A receptor, type I (ACVR1). Given once a day, the drug is designed to combat anaemia, constitutional symptoms and splenomegaly simultaneously. The FDA initially delayed its approval decision of Ojjaara by three months in June 2023 as the regulator wanted more time to process recently submitted data from GSK. The eventual approval was based on data from the phase 3 MOMENTUM study, where Ojjaara significantly improved constitutional symptoms, splenic response and transfusion independence in patients with myelofibrosis and anemia compared with danazol. GSK also submitted data from another phase 3 trial called SIMPLIFY-1 where Ojjaara showed benefits compared with ruxolitinib in a subgroup of myelofibrosis patients with anemia. The most common adverse effects in the two trials included thrombocytopaenia, haemorrhage, bacterial infection, fatigue, dizziness, diarrhoea, and nausea. “The vast majority of myelofibrosis patients eventually develop anaemia, causing them to discontinue treatments and require transfusions,” said Nina Mojas, GSK’s senior vice president, oncology global product strategy, in a public statement. “Given this high unmet need, we are proud to add Ojjaara to our oncology portfolio and address a significant medical need in the community. We look forward to helping improve outcomes in this difficult-to-treat blood cancer.” Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
GSK Investments
53 Investments
GSK has made 53 investments. Their latest investment was in Oncopole as part of their Corporate Minority on June 6, 2023.

GSK Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/6/2023 | Corporate Minority | Oncopole | $4.09M | Yes | GSK, Merck Canada, and Pfizer | 1 |
9/22/2022 | Corporate Minority - P2P - II | Spero Therapeutics | $9M | Yes | 9 | |
9/7/2022 | Corporate Minority - P2P | SpringWorks Therapeutics | $75M | No | 5 | |
3/23/2022 | Series C | |||||
1/18/2022 | Corporate Minority - P2P |
Date | 6/6/2023 | 9/22/2022 | 9/7/2022 | 3/23/2022 | 1/18/2022 |
---|---|---|---|---|---|
Round | Corporate Minority | Corporate Minority - P2P - II | Corporate Minority - P2P | Series C | Corporate Minority - P2P |
Company | Oncopole | Spero Therapeutics | SpringWorks Therapeutics | ||
Amount | $4.09M | $9M | $75M | ||
New? | Yes | Yes | No | ||
Co-Investors | GSK, Merck Canada, and Pfizer | ||||
Sources | 1 | 9 | 5 |
GSK Portfolio Exits
36 Portfolio Exits
GSK has 36 portfolio exits. Their latest portfolio exit was Haleon on July 18, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/18/2022 | IPO | Public | 1 | ||
7/17/2022 | Spinoff / Spinout | 2 | |||
6/17/2021 | Reverse Merger | 13 | |||
Date | 7/18/2022 | 7/17/2022 | 6/17/2021 | ||
---|---|---|---|---|---|
Exit | IPO | Spinoff / Spinout | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 2 | 13 |
GSK Acquisitions
22 Acquisitions
GSK acquired 22 companies. Their latest acquisition was Bellus Health on June 28, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/28/2023 | Acq - P2P | 6 | ||||
7/1/2022 | Series D | $79.83M | Acq - P2P | 8 | ||
5/31/2022 | Grant | $369.49M | Acquired | 6 | ||
9/11/2019 | Series A | |||||
12/19/2018 | Other |
Date | 6/28/2023 | 7/1/2022 | 5/31/2022 | 9/11/2019 | 12/19/2018 |
---|---|---|---|---|---|
Investment Stage | Series D | Grant | Series A | Other | |
Companies | |||||
Valuation | |||||
Total Funding | $79.83M | $369.49M | |||
Note | Acq - P2P | Acq - P2P | Acquired | ||
Sources | 6 | 8 | 6 |
GSK Fund History
1 Fund History
GSK has 1 fund, including Action Potential Venture Capital Ltd..
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/8/2013 | Action Potential Venture Capital Ltd. | Multi-Stage Venture Capital | Closed | $50M | 1 |
Closing Date | 8/8/2013 |
---|---|
Fund | Action Potential Venture Capital Ltd. |
Fund Type | Multi-Stage Venture Capital |
Status | Closed |
Amount | $50M |
Sources | 1 |
GSK Partners & Customers
10 Partners and customers
GSK has 10 strategic partners and customers. GSK recently partnered with Zuellig Pharma on August 8, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
8/1/2023 | Vendor | Singapore | Robert Kruit , EVP Strategic Partnerships & Business Development , Zuellig Pharma said : `` With the launch of GSK 's regional vaccine distribution hub , the strategic partnership between GSK and Zuellig Pharma delivers a profound , direct impact on vaccine availability in the region , while reducing the carbon footprint and setting a standard in supply chain traceability . '' | 2 | |
7/20/2023 | Licensee | Switzerland | GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine LimmaTech Biologics AG signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust . | 2 | |
7/20/2023 | Licensee | Italy | Recordati, agreement with GSK for Avodart Combodart distribution in Europe - Recordati announced Thursday an agreement with GSK to market Avodart Combodart/Duodart in 21 countries , mainly in Europe , excluding those where GSK already has distribution agreements in place . | 1 | |
7/10/2023 | Licensor | ||||
6/27/2023 | Vendor |
Date | 8/1/2023 | 7/20/2023 | 7/20/2023 | 7/10/2023 | 6/27/2023 |
---|---|---|---|---|---|
Type | Vendor | Licensee | Licensee | Licensor | Vendor |
Business Partner | |||||
Country | Singapore | Switzerland | Italy | ||
News Snippet | Robert Kruit , EVP Strategic Partnerships & Business Development , Zuellig Pharma said : `` With the launch of GSK 's regional vaccine distribution hub , the strategic partnership between GSK and Zuellig Pharma delivers a profound , direct impact on vaccine availability in the region , while reducing the carbon footprint and setting a standard in supply chain traceability . '' | GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine LimmaTech Biologics AG signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust . | Recordati, agreement with GSK for Avodart Combodart distribution in Europe - Recordati announced Thursday an agreement with GSK to market Avodart Combodart/Duodart in 21 countries , mainly in Europe , excluding those where GSK already has distribution agreements in place . | ||
Sources | 2 | 2 | 1 |
GSK Service Providers
2 Service Providers
GSK has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor | |
Service Provider | ||
---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
Compare GSK to Competitors
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. They are also committed to independent thinking and ground breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting‐edge treatments to meet the most pressing needs of healthcare professionals and patients.

Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., is a global, biopharmaceutical company bringing forward medicines and vaccines for challenging diseases.
The Grunenthal Group is a science-based pharmaceutical company that seeks to bring treatments and technologies to patients worldwide. The company focuses on pain management and related diseases.
POSVAX is a biotech company that develops vaccines targeting human papillomavirus (HPV), respiratory syncytial virus (RSV), and Alzheimer's.
Eli Lilly and Company is a drug firm that focuses on neuroscience, endocrinology, cancer, and immunology. Its key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, and Humulin for diabetes, and Taltz and Olumiant for immunology. The company was founded in 1876 and is based in Indianapolis, Indiana.

Roche (OTCQX: RHHBY) (OTCQX: RHHBF) operates as a multinational research-focused healthcare company. It discovers, develops, and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions which are the pharmaceuticals division and the diagnostics division. The company was founded in 1896 and is based in Basel, Switzerland.